Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

European Consortium Seeks Autism Drugs

by Michael McCoy
March 26, 2012 | A version of this story appeared in Volume 90, Issue 13

A newly formed consortium led by Roche, King’s College London, and the advocacy group Autism Speaks will develop drugs and other treatments for autism spectrum disorders. Called European Autism Interventions, the consortium will receive a total of $38.7 million from the European Union, corporate participants, and Autism Speaks. Goals for the five-year project include validated cellular assays, animal models, biomarkers for patient segmentation, and new radioligands for use in positron emission tomography.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.